Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes
Dolutegravir combo beats Atripla for effectiveness and tolerability
Integrated analysis shows 'Quad' pill has potent activity with fewer side-effects
Long-acting fusion inhibitor albuvirtide looks promising in early studies
Attachment inhibitor BMS-663068 does well in early study involving HIV-positive people
Once-daily elvitegravir works as well as raltegravir at 96 weeks
Cobicistat matches ritonavir as atazanavir booster
Latest data on HIV cure research
Dolutegravir matches raltegravir for people starting treatment
